Co-Founder and Partner of Sapient Capital Partners, a Toronto-based firm founded in 2005 which advises mid-sized and growth stage private companies and their owners in the areas of:
Significant senior transaction management and execution experience in a variety of industries in private company sales, acquisitions and divestitures, and corporate and capital market strategy as both advisor and principal in Canada and the U.S.
Brad has over 20 years of experience in corporate and investment banking, merchant banking, private equity/venture capital and institutional equity research.
He has long specialized in private companies, from early- to growth- to exit-stage, both as advisor and principal, and has served on a number of boards of directors and advisory boards of such companies, currently NovaVive Inc., a privately held animal health immunobiology company based in Ontario, Canada.
Trained at some of the leading North American financial institutions such as CIBC World Markets and Gordon Capital in Toronto; Bank of America in San Francisco; and JPMorgan Chase (Chemical Venture Partners) in New York.
Broad business insight from experience in wide range of industries including web & enterprise software, technology-enabled manufacturing & business services, healthcare (biotech, healthcare services, health & wellness), media & entertainment, telecom, aerospace, industrial products, consumer products, retail, chemicals, business process outsourcing (BPO), automotive and financial services.
Frequent commentator in the financial press, providing commentary on topics of private business, entrepreneurship and capital markets, including a monthly commentary called ‘Capital Insight’ for over 6 years in the National Post.
Graduate of University of Chicago's Booth Graduate School of Business, 1995 with highest honors.
Large businesses aren't the only ones that need to consider succession planning. No matter the size of your company, it's vital you are considering what happens when you...
There is a lot of advice out there on how to generate the valuation you want at time of sale. However, the main things you should be considering are positive and...